Everest Medicines Reports 1H 2026 Results, Enters New Phase as Growth Accelerates and Innovation Gains Momentum

Everest Medicines (HKG: 01952) announced its interim results for the six months ended June 30, 2026. Everest delivered strong growth and reached an important profitability milestone in the first half of 2026. Total revenue increased 157% year-on-year to RMB 1.148 billion, driven by continued commercial momentum across the company’s portfolio. Gross margin excluding non-cash items […]